Medicebran

Methylphenidate Hydrochloride, the active ingredient in Medicebran, is a central nervous system stimulant presented as an oral formulation for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults. GNH USA supplies Medicebran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Hydrochloride acts on central nervous system pathways to improve attention and reduce excessive sleepiness. - Attention deficit hyperactivity disorder (ADHD): enhances concentration, reduces hyperactivity and impulsivity. - Narcolepsy: decreases daytime sleepiness and improves wakefulness. - Attention deficit disorder (ADD): supports better focus and behavioral control.

Methylphenidate Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Insomnia - Decreased appetite - Stomach pain or nausea - Headache

Serious or Rare Side Effects: - Cardiovascular events such as hypertension or tachycardia - Psychosis or severe mood changes - Severe allergic reaction including rash, swelling, or anaphylaxis

Methylphenidate Hydrochloride requires careful monitoring in several clinical situations. - Cardiovascular monitoring: assess blood pressure and heart rate before and during therapy. - Psychiatric assessment: evaluate for history of psychosis, bipolar disorder, or severe anxiety. - Seizure risk: use cautiously in patients with a known seizure disorder. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Methylphenidate Hydrochloride can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase stimulant effects and cardiovascular strain. - Certain antihypertensive agents: can reduce blood‑pressure‑lowering effectiveness.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise methylphenidate plasma levels. - Antacids: can affect absorption, monitor therapeutic response. - Alcohol: may enhance central nervous system stimulation and increase side‑effect risk.